Abstract: The present invention relates to a hard capsule composite formulation comprising a capsule having a hemispherical closure at each end and an interior space; and one or more tablets encapsulated in the capsule, wherein the tablet or the tablets as a whole have a shape conforming to the internal space of the capsule. The hard capsule composite formulation can efficiently charge pharmaceutical compositions inside the limited interior space of the capsule, and hence, it allows packing a high-dose of pharmaceutical composition in a relatively small-sized capsule, which increases productivity and patient compliance. Also, the composite formulation exhibits good dissolution rate because pharmaceutically active ingredients contained in the capsule are separated from one another, and thus, the ingredients are less affected by the dissolution rate of one another, allowing good storage stability which can optimize the therapeutic effects.

Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.

Abstract: Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Abstract: The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells.

Abstract: An oral pharmaceutical composition of the present invention comprising fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, which is useful in treating hyperlipidemia and hypertriglyceridemia.

Abstract: A system and method is disclosed for providing an adaptive value of a TTL (Time to Live) count for broadcast/multicast messages in a wireless mesh network using a hybrid wireless mesh protocol. A mesh point controller is provided that adaptively selects the value of the TTL count and routes the broadcast/multicast message through the wireless mesh network based on the adaptively selected value of the TTL count. The adaptive selection of the TTL count in accordance with the principles of the invention significantly reduces the number of broadcast/multicast messages that must be transmitted (flooded) through the mesh network.

Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.

Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine and losartan as active ingredients, and a disintegrant which is a mixture of at least two components selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, and crosspovidone, which exhibits a high and stable level of amlodipine and losartan dissolution rates.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.

Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.

Abstract: Disclosed herein is a pharmaceutical composition comprising a part containing amlodipine or a pharmaceutically acceptable salt thereof and another separate part containing losartan or a pharmaceutically acceptable salt thereof, which exhibits improved preventive and therapeutic effects against cardiovascular disorders.

Abstract: A method and packaging machine for preparing rapidly disintegrating formulations for oral administration are disclosed. The present invention is characterized in that a powdery mixture including a pharmaceutically active ingredient and a sugar or a sugar alcohol powder is filled into a packaging material and, thereafter, the mixture, filled in the packaging material, is heated. The present invention can simply and economically prepare an oral formulation which undergoes rapid disintegration in the oral cavity and provides for high-quality administration to patients.

Abstract: Key scalability issues in the management of routing information at each node in wireless networks running a proactive routing protocol have been identified and a solution is set forth based on hybrid proactive on-demand routing with focus on the STA association information management at each MP in a WLAN mesh. A fisheye-scope-based GAB management scheme is described where the priority of an entry is the reverse of the hop count of its associated MAP/MPP from the MP, which can be easily applicable to the case of management of general routing information. For example, the GAB proposed can maintain only those entries whose associated MAPs/MPPs are two or less hops away from the MP.

Abstract: A multi-table-based grant generator in accordance with the present invention solves the issue of bandwidth granularity, while maintaining the simplicity of a table approach. The present invention grant generator provides grants of fine granularity for regulation of upstream transmission of cells in an ATM PON. Multiple grant tables having differing bandwidth granularities are linked together through a simple grant distribution mechanism. The grant tables and grant distribution mechanisms can be recursively linked to achieve a number of different granularities. The grant generator of the present invention is based on multiple grant tables with a combination of multiplexers, dividers, and address counters. The grant generator provides both larger and smaller bandwidths for data grants as well as PLOAM grants without large size grant tables. In one exemplary embodiment of the present invention, improved granularity is achieved, where a first grant table is used for one size of bandwidth grant, e.g.

Abstract: An optical network has an optical splitter connected to (1) a working optical subscriber unit (OSU) of a working circuit via a working optical fiber, (2) a protection OSU of a protection circuit via a protection optical fiber, and (3) one or more optical network terminals (ONTs). The present invention enables fast protection switching from the working OSU to the protection OSU. In one embodiment, the arrival times of corresponding upstream ranging reply PLOAM cells are measured at both the working and protection OSUs during ranging operations of the working OSU. In another embodiment, a cell delineation procedure is initiated at the protection OSU during normal, non-ranging operations of the working OSU to enable the protection OSU to correctly delineate upstream cells and the arrival times of corresponding upstream cells are then measured at both the working and protection OSUs.

Abstract: An optical network has an optical splitter connected to (1) a working optical subscriber unit (OSU) of a working circuit via a working optical fiber, (2) a protection OSU of a protection circuit via a protection optical fiber, and (3) one or more optical network terminals (ONTs), where the protection OSU has a protection burst mode receiver (BMR) configured to receive an upstream optical signal from the optical splitter. The algorithm determines whether the protection OSU is functioning improperly. A reset pulse is applied at the protection BMR at a particular timing position and an attempt is made to interpret the current upstream cell received at the protection BMR. This process is repeated using different timing positions for the BMR reset pulse until the current upstream cell is correctly interpreted, e.g., based on the correct identification of an ATM header error correction (HEC) byte in the upstream cell.

Abstract: An optical network has an optical splitter connected to (1) a working optical subscriber unit (OSU) of a working circuit, (2) a protection OSU of a protection circuit, and (3) one or more optical network terminals (ONTs), where an ONT has (i) a working line termination (LT) unit of the working circuit and connected to the optical splitter via a working optical fiber and (ii) a protection LT unit of the protection circuit and connected to the optical splitter via a protection optical fiber. The present invention enables fast protection switching from the working circuit to the protection circuit. The arrival times of corresponding downstream cells are measured at both the working and protection LT units of the ONT, and information related to the arrival times is transmitted from the ONT to the protection OSU.